Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F. Garrelfs, John C. Lieske, Jiandong Lu et al.|New England Journal of Medicine|2021Cited by 505
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A. Hulton, John C. Lieske, Jaap W. Groothoff et al.|Kidney International Reports|2021Cited by 32
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)Sander F. Garrelfs, John C. Lieske, Yaacov Frishberg et al.|Nephrology Dialysis Transplantation|2020Cited by 21
12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff et al.|Journal of the American Society of Nephrology|2020Cited by 4
MP07-08 EFFECT OF LUMASIRAN ON KIDNEY STONES AND NEPHROCALCINOSIS IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1John C. Lieske, Yaacov Frishberg, Sander F. Garrelfs et al.|The Journal of Urology|2021Cited by 0